Market Signal Briefing

Major cryptocurrency Solana (SOL) can drop to as low as $50 if a prominent trendline fails, one popular analyst argues. The 6th-largest cryptocurrency by market capitalization has been on a recovery mission since the start of 2026, with double-digit gains, but it is still under pressure as the New Year’s momentum could be fading.

SOL is currently trading at approximately $138, down 2% on a daily basis, with a daily volume of $1.9B. The market sentiment is currently upbeat, as SOL has held on to the New Year price recovery so far, but it is under pressure to continue.

Ali Charts, a popular crypto analyst with over 164,000 followers, believes the bulls need to keep SOL above a clear trendline to avoid a major price dump. He tweeted:

Image Source: X The trendline dates back to early 2023 and shows that, even amid major hiccups, the programmable digital currency has bounced off it. Ali has predicted that the trendline needs to hold; otherwise, the bears will have a field day and eventually form a bottom at around $50, registering a morale-shattering 62% price drop in the process.

Solana’s Outlook The cryptocurrency’s 14-day RSI is hovering just above 40, indicating the market is currently in a neutral or cool zone and not showing a strong inclination towards either side at the moment. The bulls will look at the current setup and see a buying opportunity, while the bears will take heart that the price recovery has stalled for now. The situation is delicately poised and could sway in either direction, provided the conditions present themselves.

Advertisement  

One X user replied to Ali’s post:

“That level really matters.

If that trendline snaps with volume, downside can accelerate fast — $50 becomes a realistic magnet.

Until then, it’s still support, but this is where risk management matters most.

Let the level decide, not conviction.”

Another quipped:

“SOL’s trendline is crucial; a break could trigger a significant drop to $50, huge risk for holders.”

Ali rounded off with this bearish prediction by sharing a GIF of the US Federal Reserve printing money. Ali’s prediction, while understandable, shows the possibility of a major price dump, but it also shows that there is potential for a major upside price action, too. The analyst is being extremely cautious regarding the future after 2025’s major hiccups.

Crypto treasury company BitMine Immersion Technologies (BMNR) staked an additional 86,400 Ether (ETH) on Saturday, valued at about $268.7 million at the time of this writing, crossing the 1 million staked ETH milestone. 

The 86,400 ETH was staked in four separate transactions, according to data from crypto market analytics platform Arkham Intelligence; this brings BitMine’s total to 1,080,512 staked ETH, onchain analysis platform Lookonchain said.

The 86,400 ETH staked by BitMine. Source: Arkham IntelligenceStaking is the process of pledging or locking up crypto tokens by validators or third-party staking service providers to secure proof-of-stake blockchain networks. 

Staking in crypto produces yield for the validator or investor, who has delegated stake via a third-party provider, paid in the native token of the blockchain network being secured.

“BitMine has now staked about $3.3 billion worth of ETH. At the current 2.81% yield, that generates roughly $94.4 million per year in ETH,” market analyst Nic Puckrin said.

“Obviously, Bitcoin doesn’t produce cash flow, Puckrin added, and asked, “If another crypto winter hits and debt comes due, does holding a stakeable asset change who weathers it better?”

The milestone was crossed following a turbulent year for crypto treasury companies, with some shedding over 90% of their value from their all-time highs. 

BitMine’s share price collapsed following the all-time high in July 2025. Source: Yahoo FinanceBitMine’s stock is down over 80% from its all-time high of $161 per share, reached in July 2025, and is trading at $30.06 per share at the time of publication.

BitMine chairman asks shareholders to approve a 1000x increase in authorized shares In early January 2026, BitMine chairman Tom Lee urged shareholders to vote yes on a proposal to increase the authorized share limit to 50 billion shares.

The proposal would raise the number of shares BitMine is allowed to issue from 50 million to 50 billion — a 1000x increase.

The number of stock splits BitMine would need at different price levels for its stock to trade at $25 per share. Source: Tom LeeIncreasing the authorized share limit does not necessarily mean the company will issue those shares, Lee clarified.

Raising the authorized share limit will accommodate future stock splits to keep Bitmine’s price-per-share affordable at about $25 per share, he said.

Magazine: Sharplink exec shocked by level of BTC and ETH ETF hodling: Joseph Chalom

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

A high-conviction trader deployed a $7.76 million 10x long on Fartcoin near range lows, signaling confidence as price compresses after months of downside exhaustion. 

Price had already completed a prolonged downtrend and shifted into sideways consolidation. Instead of chasing strength, the trader positioned into compression. 

This reflects a structural bet rather than momentum chasing. Moreover, the leverage choice amplifies intent while increasing exposure risk. 

However, whales rarely commit size without favorable risk-reward conditions. They often act when downside pressure fades. 

Fartcoin price coils tightly after the downtrend ends Fartcoin [FARTCOIN] continued trading inside a well-defined range after completing its broader downtrend. 

Price stalled repeatedly below $0.47, which stood as the nearest resistance. That level capped multiple recovery attempts.

Above it, $0.74 emerged as secondary resistance, aligning with former support that flipped into supply.

Further overhead, $0.96–$0.98 marked another rejection zone, followed by the macro ceiling at $1.20.

On the downside, range lows continued attracting buyers, consistently absorbing sell pressure.

Meanwhile, the MACD flattened near the zero line, with shallow positive histogram bars and a gradual upward curl.

That structure reflected fading bearish momentum rather than aggressive upside, suggesting stabilization beneath the price.

Source: TradingView

Open Interest rises as price stays flat Open Interest climbed 6.18% to $265.53 million while Fartcoin’s price remained range-bound.

That divergence signaled fresh leverage entering without immediate price expansion. Traders positioned in anticipation, not reaction.

Rising Open Interest during consolidation often preceded volatility expansion. However, the leverage introduced fragility.

If support held, leverage-fueled upside continuation. If it failed, leverage accelerated downside.

Still, the price absorbed added exposure calmly. That behavior reduced immediate breakdown risk. For now, Open Interest supported consolidation rather than instability.

Source: CoinGlass

Top traders lean heavily bullish Binance data showed 67.99% of top trader positions skewed long, pushing the Long/Short Ratio to 2.12.

That reflected a strong directional bias, rarely formed without conviction. Even so, crowded sentiment increased vulnerability. Failed breakouts punished longs quickly.

Here, bullish positioning aligned with basing price action and rising Open Interest. That confluence strengthened the upside case.

Still, range lows required defense. Otherwise, conviction turned into liquidation fuel.

Source: CoinGlass

Fartcoin liquidations stay contained despite leverage Liquidation data pointed to stability rather than stress across FARTCOIN Derivatives.

Total liquidations stood near $66,000, with short liquidations around $55,190 outweighing long liquidations near $11,060.

That imbalance mattered. Shorts absorbed pressure without triggering upside acceleration, while longs avoided cascading exits.

Exchange-level data showed no outsized forced selling on the long side.

Leverage entered methodically, not recklessly. Even so, equilibrium rarely persisted indefinitely. A decisive range break would likely expand liquidation flows in the breakout direction.

Source: CoinGlass

Fartcoin sat at a clear inflection point. Whale conviction, rising Open Interest, bullish positioning, and controlled liquidations pointed toward a buildup rather than a breakdown.

Even so, the range still governed direction. A break above $0.47 could shift momentum decisively. Failure kept the risk elevated.

Final Thoughts Fartcoin’s current setup reflects patience rather than panic, with leverage, positioning, and price structure holding in balance. A sustained move beyond the range could validate that buildup, while failure would quickly test trader conviction.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

The price of Bitcoin is infamous for its inactivity during the weekends, and it has not disappointed in the past day. The premier cryptocurrency continues to hover around the psychological $90,000 mark, with no significant movement observed over the past 24 hours.

While the Bitcoin price action — or lack thereof — has lulled most investors to sleep, a particular market participant has just woken from their slumber. According to the latest on-chain data, a Satoshi-era miner just moved a significant amount of Bitcoin over the weekend.

Satoshi-Era Miner Moves 2,000 BTC On Saturday In a post on the social media platform X, CryptoQuant’s head of research, Julio Moreno, revealed that a Bitcoin miner from the Satoshi era moved 2,000 coins on Saturday, January 10. This would represent the first time such movement would be occurring from this group of network participants since November 2024.

The Satoshi-era miners refer to entities that mined BTC during its earlier years, typically between 2009 and 2011, when the flagship cryptocurrency’s pseudonymous creator, Satoshi Nakamoto, was still active. At the time, mining BTC was a less competitive sport (could be done with a consumer CPU), with greater rewards.

Source: @jjc_moreno on X Moreno noted that, historically, the Satoshi-era miners have only ever moved their coins at key inflection points. In November 2024, when the last miner from this group made a transaction, the price of Bitcoin was around $91,000.

The premier cryptocurrency has since gone on to set multiple all-time highs before reaching the current cycle peak of $126,080. While it is difficult to say what the Satoshi-era miner saw before its latest move, the pattern-like nature of these coin movements makes them too relevant to ignore.

Why Bitcoin Investors Should Watch Out For $84,500  As earlier inferred, indecisiveness seems to be returning to the Bitcoin market, as the bulls and bears continue their battle around the $90,000 level. While this region has gained relevance in recent weeks, recent on-chain data has identified another crucial level beneath it.

According to Alphractal’s CEO and founder, Joao Wedson, this level is the 2-year moving average (2Y MA) of Bitcoin. The on-chain expert highlighted that this level represents the last major support cushion for the market leader.

From a historical perspective, the loss of the 2Y MA, which is currently around $84,500, could increase the probability of capitulation significantly. In essence, the premier cryptocurrency faces the risk of extended downward movement once it crosses below $84,500.

As of this writing, the price of BTC stands at around $90,435, reflecting no change in the past 24 hours.

The price of BTC on the daily timeframe | Source: BTCUSDT chart on TradingView Featured image from iStock, chart from TradingView

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Binance Coin (BNB) price extended its bullish momentum over the weekend, reaching $907 on Sunday after a notable 24-hour surge. 

The rally came as the broader crypto market gained 0.61% daily, with Bitcoin holding above the $90,000 level and Ethereum trading steadily above $3,100. This optimism was greatly caused by the remarks by Binance founder Changpeng, CZ, Zhao, who stated that the crypto super cycle might be coming.

Binance Coin Price Rises as CZ Signals Incoming Super Cycle CZ made the remarks on X in response to a major regulatory development. The U.S. Securities and Exchange Commission (SEC) has taken cryptocurrencies off its list of priority risk in 2026, a move that is largely interpreted as a positive move in the industry.

CZ cited growing institutional demand as one of the major reasons why the super cycle was likely to occur. 

I could be wrong, but Super Cycle incoming. https://t.co/6TLldEMmGA

— CZ 🔶 BNB (@cz_binance) January 10, 2026

He pointed out that when the market was going down badly, retail investors were pan-handling their way out, but big banks like Wells Fargo were sneaking in to make purchases. 

Deciding on institutional investors, Wells Fargo purchased 383 million of Bitcoin ETF shares according to a filing, as the role of institutional investors in the crypto sector grows.

Morgan Stanley excelling the wave, last week is when it filed its own spot Bitcoin ETF. The relocation shows additional trust of conventional financial institutions on digital assets.

His remarks are also based on the ultra-bullish forecast of VanEck that Bitcoin is capable of rising to $2.9 million, which like his statements adds more weight to the story of a strong imminent upward movement. 

With market sentiment changing, Binance Coin could be afflicted with an increase in interest and inflow of capital in crypto assets among investors.

Top Crypto Events That Could Boost BNB Price This Week Several major macroeconomic events are lined up this week, each of which could influence crypto prices and BNB’s next move. 

On Monday, the participants of the market will pay attention to the speech, which will be given by the FOMC President, and possibly provide an indicator of the direction of the monetary policy. 

The U.S. Consumer Price Index (CPI) and the Producer Price Index (PPI) reports on the inflation rate will be released on Tuesday and Wednesday, respectively.

New figures of jobless claims will be present on Thursday, which may indicate a shift in the labor market situation. The Federal Reserve will release an update on its balance sheet on Friday that will present more information about the liquidity trends.

All of this is developed as the market is still firm before the major U.S CPI  inflation data. Having encouraging news on the part of regulators and institutions it may indicate that the Binance Coin price is in a good position to break the $1000 price threshold in the short run.

BNB Price Poised for 10% Rally as Bulls Target the $1,000 Level The latest BNB price climbed to $909, marking a steady uptrend on the 4-hour chart after reclaiming the $900 support zone.

The next major resistance lies near $950, followed by a psychological barrier at $1,000.

The MACD indicator is showing a bullish crossover. with the blue line shifting above the signal line, giving an indication of an upward momentum. 

The positive bars also appear in the histogram, which signifies that buying pressure is accumulating.

In the meantime, the RSI is positioned at 56.10, which indicates a moderate strength without reaching the overbought state. This implies that BNB still has time to rise further, and then it can experience a possible selling pressure.

If the full Binance forecast report maintains momentum above $900, traders expect a push toward $950 in the short term. Any breach of that position would open up a way to $1,000, which is a possible 10% increase on the present price.

Source: BNB/USD 4-hour chart: Tradingview On the downside, the critical support zone is still at $850. Any fall below it may attract selling volume, which may revisit lower levels around $820.

Frequently Asked Questions (FAQs) BNB surged due to bullish momentum, CZ’s super cycle remarks, and strong institutional demand.

CZ signaled an incoming crypto super cycle driven by institutional accumulation.

The Shiba Inu (SHIB) cryptocurrency is under scrutiny this week as analysts question whether its price can maintain a level above $0.0000090. This inquiry comes at a time when market participants are closely observing the coin’s performance amid fluctuations in the broader cryptocurrency market. The focus on SHIB’s price is essential for investors looking to gauge short-term trends and potential investment opportunities.

Market observers have noted that SHIB’s recent movements are part of a larger pattern affecting many cryptocurrencies. Volatility continues to be a defining characteristic of the crypto market. For Shiba Inu, maintaining a stable price above this threshold is seen as a test of investor confidence and market strength.

Cryptocurrencies, including Shiba Inu, are known for their rapid price changes, which can be driven by various factors such as market speculation, regulatory announcements, or technological developments. The price of SHIB has experienced considerable highs and lows since its inception, reflecting broader trends in the digital asset space.

Institutional investors and retail traders alike monitor SHIB’s price closely. For institutional players, cryptocurrencies offer diversification opportunities and a potential hedge against traditional market movements. Retail investors, on the other hand, often seek quick gains from short-term price fluctuations.

Exchange-traded funds (ETFs) and other investment vehicles play a crucial role in the crypto market by providing access to a variety of digital assets. An ETF typically comprises a collection of securities, offering investors exposure to specific segments of the market. In the case of cryptocurrencies, a spot ETF would allow direct investment into a digital asset like SHIB, subject to regulatory approval processes which usually emphasize custody and investor protection.

Regulatory bodies worldwide have shown a keen interest in the cryptocurrency market, focusing on ensuring market integrity and protecting investors from potential risks. These regulators often require exchanges to implement surveillance measures to prevent market manipulation and ensure transparent operations.

Shiba Inu, often compared to other meme coins, has gained popularity due to its community-driven approach and decentralized nature. However, its reliance on market sentiment makes it susceptible to rapid shifts in value. The crypto’s underlying technology and use cases are often secondary to its perceived value within the investor community.

Despite the interest surrounding SHIB, it faces significant challenges, including liquidity issues and regulatory uncertainties. These aspects can affect its market standing and investor interest. Cryptocurrencies are often subject to operational risks such as security breaches and technical failures, which can further impact investor confidence.

The competitive landscape for cryptocurrencies is robust, with numerous projects vying for market share. This competition can lead to frequent amendments in project strategies and timelines as developers strive to innovate and capture investor interest.

As the week progresses, investors and analysts will be watching the price of SHIB closely, evaluating potential next steps. This includes possible amendments to trading strategies or adjustments in market positioning. The outcome of SHIB’s price stability will be indicative of broader market trends and investor sentiment.

Market participants are also aware of the potential for regulatory developments that could influence the cryptocurrency landscape. These developments may impact not only SHIB but the entire market, prompting stakeholders to remain vigilant in their investment decisions.

In conclusion, while the price stability of Shiba Inu remains a topic of interest, it is part of a larger narrative within the cryptocurrency market. As regulators, investors, and developers continue to navigate this complex environment, the focus on SHIB’s performance will persist as an important barometer of crypto market dynamics.

Post Views: 1

TLDR: Ethereum staking shows low exit queue and high entry queue, indicating strong validator confidence despite market uncertainty. Bitcoin MVRV ratio suggests buying opportunities, but analysts recommend waiting for realized losses before confirmation. ETF participants mirror retail investor behavior rather than bringing institutional discipline to cryptocurrency markets. Sentiment metrics and network growth spikes historically precede corrections, warranting cautious approach to current rally. Crypto markets entered 2026 with mixed signals as analysts examine staking data and sentiment metrics across major digital assets. 

Brian Armstrong hosted Maxim, CEO of Santiment, on This Week in Crypto to discuss performance trends and psychological factors affecting market timing. 

Their analysis covered top performers like XRP and Sweet while scrutinizing Bitcoin, Ethereum, and Solana fundamentals. 

The conversation highlighted increasing Ethereum staking interest alongside warnings about overhyped market conditions.

Staking Queue Data Reveals Growing Ethereum Network Interest Ethereum staking metrics show compelling changes with a notably low exit queue and high entry queue. This pattern suggests sustained confidence among validators despite broader market uncertainties. 

Maxim emphasized the challenge of accurately timing market peaks and bottoms. “The difficulty in timing the market and the need to constantly analyze data” requires adapting to new information, he noted during the discussion.

The conversation addressed a significant Ethereum network growth spike requiring historical context. Maxim cautioned that similar spikes have previously preceded price corrections. 

He expressed preference for Ethereum despite “anticipating a potential drop to the 2600-2800 range before a rise.” 

Meanwhile, sentiment data indicates declining Ethereum interest, potentially signaling a bottom formation according to established patterns.

On-chain analysis of Bitcoin’s MVRV ratio suggests possible buying opportunities for patient investors. However, the analysts stressed “the importance of seeing realized losses before a rise can be justified.” 

Retail versus whale activity remains a critical metric for understanding market dynamics. The conversation underscored how psychological factors often outweigh technical indicators when predicting short-term price movements.

Sentiment Analysis and ETF Flows Shape Market Psychology Maxim highlighted how extreme sentiment data helps identify narrative traps using MicroStrategy as a case study. 

He described it as “an example of a narrative trap where initial positive sentiment didn’t align with underlying facts.” This example reinforced the importance of basing investment decisions on current facts rather than momentum. 

Both analysts agreed on “the importance of basing decisions on the current situation and being prepared to change one’s mind.”

Solana experienced a FOMO spike connected to ETF filing announcements, demonstrating how regulatory developments drive speculative behavior. ETF inflows for Bitcoin, Ethereum, and Solana revealed that institutional participants often mirror retail investor psychology. 

The analysts observed that “ETF participants often behave like crypto retail investors,” challenging assumptions about institutional sophistication. 

This pattern questions whether institutional money brings more rational decision-making to volatile assets.

The conversation examined meme coin metrics showing notable divergence from major cryptocurrency trends. 

Additionally, Brian and Maxim discussed using “higher versus lower mentions to spot market tops” through social sentiment analysis. Zcash’s crash due to developer conflicts illustrated “the importance of tracking development activity and news.” 

The episode concluded by advising caution given signs of market overhype and expectations for an evening-out period ahead.

The new year started with a bang, but the excitement didn’t last long.

After a strong first week, the crypto market has fallen back into its all-too-familiar cycle of ups and downs. Bitcoin [BTC] and Ethereum [ETH] both made negligible moves, with weekly losses of 0.95% and 1.60%.

So how did the rest of the market hold up?

Weekly winners Polygon [POL] –  Usage numbers skyrocket What makes POL’s rally stand out is that the network didn’t flinch while the price took off. Daily active addresses held steady through early January, with transactions climbing in step with other major EVM chains.

Source: TradingView

Polygon [POL] pushed nearly 50% higher in a short span, breaking out cleanly with expanding volume. RSI was overbought, and capital didn’t rush out yet.

As long as activity stays firm and users keep showing up, the move up is set to go much higher.

Virtuals Protocol [VIRTUAL] – Hitting supply with little panic selling After a run-up, Virtuals Protocol [VIRTUAL] price action has slowed down too. However, this looks like momentary trouble, with gains of 22% posted at press time.

The coin pulled back after a high-volume supply zone just above the $1.05-$1.10 range.

Volume Profile data showed heavy prep around the $1.00 mark, which may be why price stalled and slipped instead of pushing straight through.

Importantly, this wasn’t a breakdown. RSI hit 63 at the time of writing, which means momentum was slowing without giving in. Price held well above the $0.85 support zone, where earlier demand stepped in.

For now, it may be consolidation under resistance.

JasmyCoin [JASMY] – Rose and stopped just as fast JasmyCoin [JASMY] had a strong week, going from the $0.0065 region and pushing above $0.0095 before slowing down. The surge came with higher volume, which means the rally had real substance and is likely to hold.

Since then, price has started to go sideways in a tight range, so the market is probably taking a moment to assess after the run.

RSI was elevated and MACD was in positive territory, so bullish momentum was intact. As long as JASMY holds above the $0.0065-$0.0067 support zone, it is expected that the coin will consolidate.

Other notable winners Privacy coin Monero [XMR] climbed around 11%, which is interesting, considering other top privacy coins posted big losses.

Render [RENDER] surged nearly 25%, benefiting from recent interest in decentralized compute and AI-linked infrastructure. Meanwhile, Artificial Superintelligence Alliance [FET] posted gains of about 15%.

By the looks of it, traders seem to be rotating into specific themes and narratives.

Weekly losers Midnight [NIGHT] – Certainly exhausted, but not worn down yet Midnight [NIGHT] had a rough stretch, down 22% from its local high before finding some footing. It looked like the coin lost steam than anything else.

Source: TradingView

The red candles came as price hit a dense supply zone near $0.09, where Volume Profile showed heavy prior positioning. What’s interesting is what followed.

Selling pressure fell quickly, and the price has started to stabilize around $0.067. RSI was in neutral territory at press time, so the bears weren’t fully in control.

If buyers defend this zone, Midnight could build a base that traders often miss.

ZCash [ZEC] – Fell hard, but selling is losing its bite Zcash [ZEC] took a hit this week, sliding nearly 26% from the $510 area before finding support near $370. On the surface, that looks ugly. But the worst of the selling may already be behind it.

RSI dipped deep into oversold territory, while CMF stopped accelerating lower. Capital outflows are slowing.

The reaction near support is notable. Despite heavy red candles earlier, recent price action had started to flatten, so sellers were running out of urgency.

If ZEC holds this zone, the next move is likely to be an uncomfortable bounce.

Canton Network [CC] – Tripped, but didn’t quite fall Most privacy-focused tokens have had a rough week, with several names struggling to hold recent gains. Canton [CC], however, has more to it than just a surface-level fall.

After an early push higher, price pulled back about 18% from local highs and has since settled near the $0.13 region. That retracement looks controlled.

Price was above the lower Bollinger Band, so volatility is low. RSI was firmly neutral, while OBV flattened instead of breaking down; distribution hasn’t taken over… yet.

Sellers are present, but confidence is weak. If privacy narratives regain footing, Canton looks positioned to stabilize first.

Other notable losers Uniswap [UNI] slipped about 7%, as trading activity cooled across major DEXs. Dash [DASH] fell nearly 13%, with weakness in the privacy coin bracket.

Dogecoin [DOGE] dropped around 8%, so even the high-visibility memecoins weren’t immune.

Conclusion At the end of the day, this market doesn’t reward rushing in or out. Some moves will stick, some won’t… and sometimes it isn’t obvious which is which in real time.

So take the signals, double-check the data, and DYOR before making any calls.

Final Thoughts While Bitcoin and Ethereum slipped under 2%, select altcoins surged as high as 50%. Usage, volume, and narrative strength mattered more than talk this week.

With investors turning their attention to precious metals, some of the best mining companies in the world are coming into their own, including this Canadian leader.

Over the long run, the stock market has been the top performer among investment asset classes. Bonds, commodities, foreign currencies, real estate, and other assets have had their moments in the sun, while cryptocurrencies have crushed the performance of traditional investments over a relatively short 17-year history. But The Motley Fool has paid the most attention to stock investing because of its time-tested track record over more than a century.

But here with my Voyager Portfolio, I'm deliberately looking at stocks that the Fool hasn't covered. That led me to choose a company from the precious metals mining industry as the portfolio's fourth stock. Agnico Eagle Mines (AEM +2.50%) shot the lights out with its returns in 2025, benefiting from soaring prices of gold and silver. That raises a simple question: Was last year's moonshot just another short-term blip in the long history of zig-zag moves for precious metals, or is some more fundamental change in the markets prompting a different way of valuing gold and silver? In this first article of a three-part series, you'll learn why gold and silver investors are bullish about their market and how Agnico Eagle Mines is poised to take advantage.

Image source: Getty Images.

From a store of value to a backdoor AI play Precious metals have enjoyed a special status in the financial markets for millennia. Gold was the primary store of value in many cultures well into the 20th century, and even after sovereign governments went off the gold standard, plenty of investors have still insisted on the superiority of the yellow metal as "real money." The reputation that precious metals have is strong enough that competing assets try to play off it, such as Bitcoin's (BTC +0.26%) characterization as "digital gold."

Gold jumped 66% in 2025, but its oft-neglected counterpart, silver, soared 144%. Silver has traditionally taken its place as second fiddle to gold, given its relative abundance and much lower price. However, silver has the advantage of being used in a wide variety of industrial applications that create additional demand beyond its monetary value. In particular, silver's favorable electrical conductivity has made it a vital part of several key technologies, including solar panel energy conversion, electric vehicle power transmission, and processors within data centers. Indeed, the U.S. Geological Survey added silver to its list of critical minerals in November 2025, demonstrating the value that the federal government places on encouraging production of the white metal.

Why Agnico Eagle stands out Agnico Eagle Mines is the world's second-largest gold producer. The company has assets around the world in Australia, Mexico, and Finland, but the bulk of its operations are in two regions of its home country of Canada. Several key properties, including the Detour Lake and Canadian Malartic mines, are located along the Ontario-Québec border south of Hudson Bay. Others are located in Nunavut in the Canadian North, where Agnico Eagle puts its expertise mining in harsh weather conditions to the test.

Today's Change

(

2.50

%) $

4.67

Current Price

$

191.14

In addition to its producing mines, Agnico Eagle has also spent time exploring other projects. Key pipeline assets like Hope Bay in Nunavut, Upper Beaver in Ontario, and Wasamac in Québec have considerable potential to add to the mining company's overall production over time.

Agnico Eagle offers investors one key advantage that many other miners lack: political stability. With its assets located primarily in developed countries with established governments and well-defined rule of law, the Canadian miner avoids some of the challenges involved in working in more turbulent parts of the world.

Agnico Eagle's golden path to soaring profits Rising prices of gold and silver have helped Agnico Eagle and its mining peers generate impressive shareholder returns. However, there's more to the gold miner's success than just rising bullion prices. The next article in this three-part series for the Voyager Portfolio will focus on Agnico Eagle's competitive advantages and how the miner has translated them into financial prosperity.

This direct-to-consumer eyewear company, known for its integrated retail and digital model, just reported a significant insider sale.

David Abraham Gilboa, co-chief executive officer of Warby Parker (WRBY +0.07%), sold 94,906 shares in multiple open-market transactions from Tuesday through Thursday, as disclosed in a recent SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)94,906Transaction value$2.61 millionPost-transaction shares (direct)37,247Post-transaction value (direct ownership)$1.05 millionTransaction value based on SEC Form 4 weighted average purchase price ($27.51); post-transaction value based on Thursday market close ($28.30).

Key questionsWhat was the rationale and mechanism behind this sizable share disposition?
The transaction involved the conversion and sale of derivative securities (options on Class A Common Stock), executed under a pre-established Rule 10b5-1 trading plan, signaling planned share monetization rather than opportunistic trading.How does the sale compare to the insider's prior selling activity?
This trade was in line with the recent median sell size of 84,953 shares, but the percentage of holdings sold (71.82%) far exceeded the recent median of 22.31%, reflecting the diminished remaining direct equity available for sale.What is the post-sale position, and how does it affect future insider sale capacity?
Following this transaction, Gilboa’s direct equity stake stands at 37,247 shares (0.03% of shares outstanding); however, he still holds a substantial number of shares through derivative securities.Did indirect holdings or related entities participate in this transaction?
No indirect holdings or related entities were involved; all shares sold originated from direct personal holdings, with indirect ownership standing at zero after the transaction.Company overviewMetricValueRevenue (TTM)$850.58 millionNet income (TTM)$717,0001-year price change11.77%Company snapshotWarby Parker offers prescription eyeglasses, sunglasses, contact lenses, and related accessories, as well as eye exams and vision tests through retail stores and digital channels.The company operates a vertically integrated, direct-to-consumer business model, generating revenue primarily from eyewear product sales and vision services.It targets value-conscious consumers in the United States and Canada seeking affordable, stylish eyewear and accessible vision care.Warby Parker is a leading direct-to-consumer eyewear company with a growing retail footprint and a strong digital presence. The company leverages a vertically integrated model to control costs and deliver value to customers, while expanding its reach through both physical stores and online platforms. Its differentiated approach combines accessible price points, design-forward products, and integrated vision care services to compete effectively in the eyewear market.

What this transaction means for investorsEven after a strong operational year, Warby Parker shares continue to lag broader benchmarks, with the S&P 500 up roughly 18% over the same period that's seen WRBY stock up about 11%. That said, the Form 4 shows the sale was executed under a Rule 10b5-1 trading plan adopted in September, signaling a preplanned move rather than a reaction to near-term developments. Also of note, the shares sold were Class A common stock derived from derivative positions, and Gilboa retains very meaningful exposure through remaining equity and derivative holdings.

Operationally, Warby Parker’s latest earnings reinforce steady progress. Third-quarter revenue rose 15% year over year to $221.7 million, while net income swung to $5.9 million from a loss a year earlier. Adjusted EBITDA reached $25.7 million, lifting margins to 11.6%, and active customers grew more than 9% on a trailing 12-month basis.

Ultimately, insider selling under structured plans is not uncommon, but sustained upside hinges on whether Warby Parker can translate improving profitability and customer growth into returns that consistently outpace the market.

GlossaryNet sold: The total number of shares sold minus any shares bought during the same period.
Open-market transaction: A trade executed on a public exchange, not through private negotiation or company programs.
SEC Form 4: A regulatory filing disclosing insider trades of company securities by officers, directors, or major shareholders.
Weighted average price: The average price per share, weighted by the number of shares traded at each price.
Derivative securities: Financial instruments whose value is based on the price of an underlying asset, such as stock options.
Class A common stock: A specific class of company shares, often with distinct voting rights or privileges.
Direct holdings: Shares owned personally by an individual, not through trusts or other entities.
Indirect holdings: Shares owned through trusts, family members, or other entities, rather than directly.
Rule 10b5-1 trading plan: A prearranged plan allowing insiders to sell shares on a fixed schedule, reducing accusations of insider trading.
Insider sale capacity: The amount of company stock an insider still owns and could potentially sell.
Vertically integrated: A business model where a company controls multiple stages of its supply chain or production process.
TTM: The 12-month period ending with the most recent quarterly report.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Warby Parker. The Motley Fool has a disclosure policy.

About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. - Get the latest news and data at finance.yahoo.com - Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) - Follow Yahoo Finance on social: X: http://twitter.com/YahooFinance Instagram: https://www.instagram.com/yahoofinance/?hl=en TikTok: https://www.tiktok.com/@yahoofinance?lang=en Facebook: https://www.facebook.com/yahoofinance/ LinkedIn: https://www.linkedin.com/company/yahoo-finance

The leading auto insurer's stock looks cheaper than it has in a while, but the reasons behind the discount warrant a closer examination.

Rarely has Progressive (PGR +0.85%) stock looked cheap. It is one of the best-run auto insurers in the U.S., with shares usually trading at a premium compared to most insurers. But after sliding about 21% from their all-time highs, shares finally resemble a bargain -- at least on the surface.

So, is this pullback a rare chance to buy a high-quality insurer at a more reasonable valuation? Or is the stock's slide a sign of more trouble ahead?

Image source: Getty Images.

Why the business looks strong It's not like Progressive's recent business growth has been unimpressive. Through the first nine months of 2025, the company reported net premiums written of $63.7 billion -- up 13% year over year. And its net premiums earned rose 17% to $60.6 billion.

For those who don't follow insurance stocks closely, premiums are simply the amount of money customers pay the company for coverage. The key difference in net premiums written and net premiums earned is timing. Net premiums written are closer to the time of sale, reflecting the amount of new and renewed coverage Progressive put on the books during the period. Net premiums earned, on the other hand, are what Progressive actually counts as revenue during the period because it has already provided that coverage.

So, when both net premiums written and net premiums earned are rising at double-digit rates, it usually means the insurer is bringing in more business and then successfully turning it into recognized revenue -- often because it's adding customers, charging higher average prices, or both.

Another factor reflecting Progressive's impressive growth is its policy growth. At the end of Q3, the company reported total policies in force of 38.1 million -- up 12% year over year.

But how's the company doing net of insurance claims and operating expenses? To find out, investors can examine Progressive's combined ratio, which compares the amount an insurer pays out in claims and operating costs to the premiums it collects. A combined ratio below 100, therefore, means the insurer made an underwriting profit on its insurance business.

Progressive remains a class act on this front, with a combined ratio of 89.5% in Q3.

A bargain price? But what really makes Progressive attractive is its valuation. Shares currently trade at about 13.4 times forward earnings (forward earnings refers to analysts' consensus estimate for Progressive's earnings over the next 12 months). Even more, it trades at 3.6 times book value. This is notably down from a multiple that approached 7 in early 2025.

But is Progressive stock really a bargain at this price? Not necessarily. There have been periods years ago in which the company regularly traded at even lower price-to-book values. So, even though Progressive's valuation looks low in the context of the last few years, it doesn't look cheap in the context of the stock's entire history.

Of course, the company solidified its leadership position in U.S. auto insurance recently. So, it probably deserves to trade higher valuation multiples than it used to. Still, I don't think the stock is cheap at its current price. Instead, it's probably closer to fairly valued.

Today's Change

(

0.85

%) $

1.81

Current Price

$

214.96

Numerous risks The stock's recent weakness comes as investors were reminded that the company operates in a regulated industry. Management recently recorded a $950 million accrual related to a Florida statute requiring insurers to return profits exceeding a specified limit to policyholders. This added 4.6 percentage points to its third-quarter combined ratio.

Additionally, Progressive is susceptible to the broader cycles of the auto insurance industry, which can swing from a hard market (characterized by price increases and strong profits) to a soft market (characterized by increasing competition, as well as challenged pricing and profits). And after years of being in a hard market, some investors may worry that the market is entering a softening.

Finally, there is a longer-term question that is harder to handicap: what happens to auto insurance if driving becomes dramatically safer due to advanced driver assistance systems and, eventually, more autonomous driving? Fewer accidents would likely result in fewer claims over time, which could reduce the total pool of profit dollars available to insurers. This is not a near-term issue, but it is a real uncertainty some investors might be beginning to discount.

What makes Progressive stock a buy There is one thing, however, that we haven't mentioned yet that, when combined with other factors like strong growth and a conservative valuation, makes the difference for me and ultimately makes me think shares are worth buying now: Its dividend policy, which includes an occasional special dividend. For example, on top of Progressive's $0.10 quarterly dividend, the company paid out a special dividend of $13.50 last week. It also paid a $4.50 one in 2025 and $0.75 special dividend in 2024.

The reason I like Progressive's special dividend policy is that every meaningful payment to shareholders takes some risk off of the table. And given the uncertainty in the auto industry, this is an especially valuable perk for shareholders. Of course, there's no way to know when or how much Progressive's next special dividend will be, but since the company has made a habit of paying them, it wouldn't be surprising to see another special dividend in 2027.

Overall, Progressive's pullback makes the stock more interesting. The company is still growing quickly, its underwriting results have been strong, and the valuation now looks more forgiving than it did near its all-time high. But the discount may also flag some real risks, including the possibility of the auto insurance market turning soft or autonomous driving technology eventually disrupting the space.

In short, I think the stock looks like a good bet over the long haul from its current price. But given the risks, investors interested in buying the stock should keep the position small.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of America's Car-Mart, Inc. (NASDAQ: CRMT) resulting from allegations that America's Car-Mart may have issued materially misleading business information to the investing public.

So What: If you purchased America's Car-Mart securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46025 https://rosenlegal.com/submit-form/?case_id=39889 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 4, 2025, during market hours, Benzinga published an article entitled "America's Car-Mart Stock Plunges After Sales Volume Dip, Delinquency Uptick." The article stated that America's Car-Mart, Inc. stock was trading "lower after the company reported first-quarter results. The company reported a first-quarter loss of 69 cents per share, compared with a net loss of 15 cents per share in the year-ago period."

On this news, America's Car-Mart's stock fell 18.2% on September 4, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline.

So what: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Skye Bioscience, Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=48064  or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding Skye's business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than defendants had led investors to believe; (2) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Skye Bioscience class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

With well-publicized losses for companies including UnitedHealth Group NYSE: UNH, Elevance Health NYSE: ELV, and Wegovy and Ozempic maker Novo Nordisk NYSE: NVO, the healthcare sector failed to outperform the broad market last year. 

Vanguard Health Care ETF Today

VHT

Vanguard Health Care ETF

$292.97 -1.32 (-0.45%)

As of 01/9/2026 04:10 PM Eastern

52-Week Range$234.11▼

$298.61Dividend Yield1.58%

Assets Under Management$17.73 billion

In the three years prior to that, the sector finished with gains of just 2.6% in 2024 and 2.1% in 2023, and a loss of 2.0% in 2022. 

Get VHT alerts:

But healthcare stocks have appeared to turn a corner. Over the past six months, the sector—which enjoys inelastic demand—has led all 11 sectors of the S&P 500 with a nearly 19% gain. 

According to investment professionals, the trend that began in mid-2025 is likely to continue into the new year.

For shareholders of the Vanguard Health Care ETF NYSEARCA: VHT, that is already proving to be true. 

2 Major Catalysts for the Health Care Sector  There are two major tailwinds that should help health stocks continue to enjoy this bullish momentum. One—the mass adoption of weight loss drugs—was partly responsible for the sector’s bullish reversal halfway through 2025. The other—comparatively low valuations—could continue to attract inflows as investors look to lock in profits and hedge against positions that present more inherent volatility.     

America’s Weight Loss Treatment Craze Weight loss treatments including GLP-1 agnostics and semaglutide treatments such as Novo Nordisk’s products Ozempic as Wegovy are becoming widely adopted. 

At the same time, pharmaceutical companies are shifting from injectable treatments to pill form, while others, like Pfizer NYSE: PFE, are doubling down on their investments in the weight loss market. 

Speaking on the popularity of these drugs, Catherine Brown, vice president of clinical services at digital health firm Welldo, recently told Reuters that “We're imagining these medications may become so common that everybody's got a GLP-1 app ... right there on your phone next to your bank account." 

Forecasts from industry consultancy firm Grand View Research indicate that the GLP-1 drug market could grow by a compound annual growth rate of 18.54% between 2024 and 2030, resulting in a global market value increase from $13.84 to $48.84 billion.

Low Healthcare Stock Valuations Are Attracting Inflows  In the wake of President Trump’s tariff announcements in April 2025—trade policies that have had an adverse effect on imported pharmaceuticals—stocks operating in the health care sector have experienced almost comically low valuations, particularly when juxtaposed with the historically high valuations of tech and communication services stocks.  

Pfizer, for example, sports a trailing 12-month (TTM) price-to-earnings (P/E) ratio of 14.7, while Health benefits provider Elevance and Johnson & Johnson NYSE: JNJ have P/E multiples of 15.32 and 19.86, respectively. 

For context, tech favorites such as Palantir NASDAQ: PLTR and Tesla NASDAQ: TSLA have TTM P/E multiples of  421.11 and 290.53, respectively. 

In turn, it was only a matter of time until health care’s ratios caught the eye of value investors looking for opportunities at the tail end of 2025 and heading into 2026. 

In November 2025, Mizuho’s healthcare equity strategist Jared Holz told Barron’s that  “When you see money come out of a space, especially one that’s filled with trillion-dollar [tech] companies, it really doesn’t take much to get some of the underperforming sectors a little juice.”

Vanguard’s VHT: A Basket of Undervalued Stocks The Vanguard Health Care ETF is up 2.30% this year after gaining more than 18% over the past six months. Much of those gains were fueled by rebounds and strong end-of-year performances from the fund’s top holdings. 

Vanguard Health Care ETF (VHT) Price Chart for Sunday, January, 11, 2026

Those positions include the ETF's top five holdings: Eli Lilly NYSE: LLY, AbbVie NYSE: ABBV, Johnson & Johnson, UnitedHealth, and Merck NYSE: MRK.  

Drilling down further into the holdings, VHT also has allocations to Pfizer, CVS Health NYSE: CVS, which acquired health insurance giant Aetna on Nov. 28, 2018, and the United States’ largest hospital chain HCA Healthcare NYSE: HCA.

The ETF carries a negligible expense ratio of 0.09% while paying a dividend that currently yields 1.58%, or $4.64 per share annually. 

What Wall Street Thinks About VHT Based on analysts’ ratings of 23 companies in the VHT portfolio (64.3% of its total), the fund receives a Moderate Buy rating.

Perhaps the strongest indication of Wall Street’s enthusiasm about the health care sector is the ETF’s current short interest of just 0.33% of the float, or less than 195,000 shares of the 60.17 million shares outstanding. That marks a nearly 37% decrease in short interest since the last reporting period.

Should You Invest $1,000 in Vanguard Health Care ETF Right Now?Before you consider Vanguard Health Care ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanguard Health Care ETF wasn't on the list.

While Vanguard Health Care ETF currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Tesla‘s (Nasdaq: TSLA) stock is at a crossroads. Investors are now more interested in fields like building a fleet of robotaxis, progress in robotics, and future addressable energy markets relative to how many car deliveries the company achieves in a given quarter. Overall, while Tesla’s 10-year chart is incredible, the company’s stock has underperformed the broader market across the last five years.

We took a look at some alternatives to NVIDIA and ranked each company by their ability to reshape transportation.

5. Rivian: The Amazon-Backed Survivor Rivian Automotive (NASDAQ:RIVN) delivered 42,247 vehicles in 2025, down 18% year over year, yet the stock surged 49% over the past 12 months. The company’s $23.8 billion market cap reflects investor belief in its Amazon delivery van partnership, optimism around its upcoming R2, and adventure-focused consumer trucks. Third quarter revenue hit $1.56 billion, up 78% year over year, though the company still burns cash with a negative 3.1% gross margin.

Reddit’s retail crowd sees Rivian as the scrappy American underdog, with consistent bullish sentiment scores between 62 and 64. One WSB user captured the market’s confusion: “Rivian delivered 42,247 vehicles, down 18% year over year, while NIO delivered 326,028 vehicles, up 47% year over year. Despite this, Rivian’s market cap is about $24B, compared to NIO’s $11B.” That valuation gap shows how much faith investors place in American EV makers versus Chinese competitors, even when the numbers don’t support it.

While Rivian might have broad support amongst the retail crowd, its ability to reshape transportation is still far more limited than other names on our list.

4. QuantumScape: The Battery Breakthrough Bet QuantumScape (NYSE:QS) has zero revenue, burns through cash every quarter, and gained 99% over the past year. The company’s solid-state battery technology promises faster charging and longer range than current lithium-ion batteries. At a $6.92 billion market cap with no commercial product, this is pure speculation on a technological breakthrough hitting commercialization in the next five years.

Wall Street currently estimates revenue of $6 million in 2026, $57 million in 2027, $379 million in 2028, and $1.2 billion in 2029. Wall Street doesn’t see the company reaching profitability until that 2029 timeframe.

24/7 Wall St. utilizes a proprietary sentiment score that tracks retail interest in stocks with 100 being extremely bullish and 0 being fully bearish. QuantumScape’s sentiment score swung from 84-88 in late December to 20-28 by early January, reflecting the extreme volatility of betting on unproven technology. The stock trades at $11.04. If the technology works, early investors could see Tesla-like returns. If it doesn’t, they’ll watch their money evaporate.

3. XPeng: The Chinese Efficiency Play XPeng (NYSE:XPEV) posted the second strongest one-year return in this group at 75%. The company generated $10.1 billion in trailing twelve-month revenue, up 102% year over year in Q3, with a 20.1% gross margin that is slightly higher than Tesla’s recnt quarter of 18% gross margins. At a $19.2 billion market cap, XPeng trades at a fraction of Rivian’s valuation despite delivering nearly eight times more vehicles.

The catch is regulatory risk. Chinese EV makers face potential tariffs, geopolitical tensions, and questions about data security that keep many American investors away. But if you believe the future of EVs is affordable mass-market vehicles rather than premium trucks, XPeng’s execution and profitability trajectory look compelling. Reddit maintains steady bullish sentiment between 62 and 68.

2. Tesla: The Struggling King Tesla (NASDAQ:TSLA) gained just 10% over the past year, underperforming every stock on this list. The company’s 2025 deliveries fell 8.6% to 1.6 million vehicles, marking its biggest annual decline ever. Meanwhile, Chinese rival BYD sold 2.26 million EVs, officially dethroning Tesla as the world’s largest EV seller.

As one Reddit user noted, “In 2011, Tesla CEO Elon Musk dismissed Chinese electric vehicle maker BYD as a competitor. But some 14 years later, BYD beat the American EV pioneer at its own game.” Tesla’s $1.50 trillion market cap reflects faith in future robotaxi and humanoid robot businesses rather than current vehicle sales. The stock trades at 311x earnings, pricing in a future that hasn’t arrived yet. Musk promised robotaxi service would reach half the U.S. population by year-end 2025, but the rollout remains limited to Austin and San Francisco.

So, why is Tesla still number two on the list? NVIDIA CEO Jensen Huang recently said “the ChatGPT moment for physical AI is here – when machines begin to understand, reason, and act in the real world.” Massive advancements in vision language action models could not only change the trajectory of self-driving cars, but also robotics.

With massive breakthroughs happening in physical AI, Tesla can’t be discounted as the company has made a massive push into robotics (Optimus) and while Robotaxi service is still limited to a small number of geographies, it can’t be counted out. 2026 will likely be the most important year in Tesla’s history, as the market either prices them as a leader in this massive fields, or could price in large multiple compression if there are fears Tesla’s approach to either robotics or self-driving cars is behind competitors like NVIDIA, Waymo, and Chinese companies.

1. Nvidia: The Real Winner Nvidia (NASDAQ:NVDA) gained 37% over the past year by selling the AI infrastructure everyone else needs. The company’s $4.58 trillion market cap dwarfs every other name on this list combined. Third quarter revenue hit $57 billion, up 63% year over year, with 73% gross margins.

CEO Jensen Huang just announced plans to power a robotaxi service with a partner by 2027, directly challenging Tesla’s core future business. The company’s new Vera Rubin AI platform promises 4x fewer GPUs needed for training versus previous generation Blackwell systems, with 10x lower inference token costs. As Huang explained on the recent launch, “Rubin arrives at exactly the right moment, as AI computing demand for both training and inference is going through the roof.”

And the company’s launch of its Alpamayo self-driving suite entrenches NVIDIA’s status as an alternative to Tesla’s Robotaxi network. While Telsa has a long lead with its FSD stack, NVIDIA’s Alpamayo provides a viable alternative across the automotive industry. It’s effectively what ‘Android’ was for smartphones in the self-driving race.

Reddit’s retail crowd remains bullish with sentiment scores between 61 and 71, far more stable than the wild swings seen in pure EV plays. One user’s observation captures why Nvidia wins: “Still, neither AMD nor its own customers are likely to unseat Nvidia from its AI throne anytime soon. And if it’s able to continue its yearly release schedule, it will be even more difficult for them to catch up.”

If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:

Answer a Few Simple Questions.  Get Matched with Vetted Advisors  Choose Your  Fit  Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)

San Francisco, California--(Newsfile Corp. - January 11, 2026) - National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Stride, Inc. (NYSE: LRN) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 12, 2026. The firm urges investors who suffered substantial losses in LRN to contact Hagens Berman now to discuss their rights.

The lawsuit seeks to recover investor losses sustained after the purported disclosure of two distinct, alleged fraudulent schemes: inflated enrollment figures (using "Ghost Students") and a catastrophic technology platform failure. The cumulative impact of these disclosures caused the stock to crash 54% in a single day, leading to a sudden loss of billions in market capitalization.

The complaint details how Stride and its executives allegedly misled investors about core business metrics and operational stability. The subsequent revelation of the severity of the platform upgrade failure-which CEO James Rhyu acknowledged resulted in "poor customer experience"-is alleged to have contradicted prior assurances of strong growth.

For a detailed breakdown of the fraud allegations and operational failures, visit the dedicated Hagens Berman Stride (LRN) Case Page.

"Stride's alleged conduct in the pending suit is particularly egregious, as the complaint alleges a systematic practice of inflating enrollment figures with 'Ghost Students' and maintaining improper student-to-teacher ratios just before revealing a foreseeable technological failure," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. "We are specifically focused on gathering evidence linking these alleged compliance and operational failures to the 54% crash."

The Alleged Dual Fraud: Claimed "Ghost Student" Scheme and Platform Upgrade Failure

The litigation focuses on how two distinct, undisclosed operational failures corrected the market's misperception of Stride's true financial health.

The Alleged Enrollment Fraud & Compliance Risk:The Claim: The company allegedly utilized unlawful business practices, including retaining "Ghost Students" (students who never officially started or were absent for extended periods) to artificially inflate enrollment metrics and profit margins.

Financial Impact: The initial disclosure that partially revealed these undisclosed facts led to an 11% stock drop.

The Alleged Concealed Technology Catastrophe:The Claim: Stride allegedly failed to disclose severe, known issues with a critical platform upgrade implemented over the summer, which blocked access for an estimated 10,000 to 15,000 enrolled students, stifling growth and requiring costly remediation.

Financial Impact: The alleged revelation of this operational failure forced the company to forecast a dramatically slowed sales growth of only 5% (down from its historical 19%), and triggered the single-day 54% stock crash.

Alleged Recoverable Damages and the Defined Class:The complaint seeks to recover losses for investors who purchased LRN securities during the Class Period (October 22, 2024 - October 28, 2025), seeking to hold Stride and certain of its key executives accountable for the alleged misrepresentations regarding core business metrics and operational stability.

Next Steps: Contact Partner Reed Kathrein Today

Hagens Berman is a leading plaintiff litigation firm recognized for securing substantial recoveries for investors in complex securities fraud cases involving operational and compliance failures.

Mr. Kathrein is actively advising investors who purchased LRN securities during the Class Period and suffered significant losses due to the alleged undisclosed facts.

The Lead Plaintiff Deadline is January 12, 2026.

TO SUBMIT YOUR STRIDE (LRN) LOSSES NOW PLEASE USE THE SECURE FORM BELOW:

Submit Your Stride (LRN) Investment Losses NowContact: Reed Kathrein at 844-916-0895 or email [email protected]: www.youtube.com/watch?v=URF8i7umlyYWhistleblowers: Persons with non-public information regarding Stride should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280006

Source: Hagens Berman Sobol Shapiro LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

This AI-driven security firm, known for touchless screening systems, reported a notable insider sale amid strong one-year share gains.

On Monday, John Kedzierski, the president and CEO of Evolv Technologies Holdings (EVLV +0.84%), completed an open-market sale of 74,322 directly held shares, following the exercise of 207,000 options, as disclosed in an SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)74,322Transaction value$522,483.66Post-transaction shares (direct)140,678Post-transaction value (direct ownership)$1.03 millionKey questionsWhat was the structure and context of this transaction?
The reported sale followed the exercise of 207,000 options, with 74,322 shares sold in the open market and the remainder retained as direct holdings, as indicated in the Form 4 and derivative transaction disclosures.How does this sale affect Kedzierski's direct stake in Evolv Technologies Holdings?
The sale reduced direct ownership by 34.57%, from 215,000 to 140,678 shares, while leaving no indirect holdings, per the SEC filing.How did market pricing at the time of sale compare to recent trading levels?
Shares were sold at $7.03 per share, with the stock closing at $7.31 on Jan. 5; this equates to a one-year total return of 132.69% as of the transaction date.Company overviewMetricValuePrice (as of Monday)$7.03Market capitalization$1.2 billionRevenue (TTM)$136.50 million1-year price change132.69%Company snapshotEvolv Technologies offers AI-driven touchless security screening systems, including Evolv Express and Evolv Edge, which are designed to detect weapons and explosives as individuals pass through at walking speed.The company generates revenue through the sale of hardware, software subscriptions, and analytics platforms that provide security insights and operational data to clients.It serves venues with high foot traffic, such as stadiums, schools, entertainment venues, and other public spaces requiring advanced security solutions.Evolv Technologies Holdings operates at the intersection of security and artificial intelligence, delivering scalable, touchless screening solutions for public venues. The company's focus on rapid, non-invasive threat detection addresses growing demand for efficient security in high-traffic environments. Its integrated analytics and AI-driven approach differentiate its offerings within the security and protection services industry.

What this transaction means for investorsTransactions tied to equity vesting can raise questions at first glance, but they often say more about tax mechanics than conviction, especially when paired with improving fundamentals.

In this case, the Form 4 shows the sale was executed solely to cover withholding taxes triggered by the vesting of restricted stock units, not a discretionary reduction in exposure. After the sale, John Kedzierski continues to hold a sizable direct stake, and there are no other dispositions on record.

The more durable story sits in the operating results at Evolv Technologies Holdings. In the third quarter, revenue rose 57% year over year to $42.9 million, while annual recurring revenue climbed 25% to $117.2 million. Losses narrowed sharply, with adjusted EBITDA turning positive at $5.1 million, and management raised full-year 2025 revenue guidance to $142 million to $145 million, implying up to 40% growth.

Ultimately, though shares are up a staggering 133% this past year, this sale looks to say more about tax planning than a change in conviction.

GlossaryOpen-market sale: Selling securities on a public exchange rather than through a private transaction.
Option exercise: The act of using stock options to buy shares at a predetermined price.
Form 4: A required SEC filing disclosing insider trades by company officers, directors, or major shareholders.
Direct holdings: Shares owned and controlled directly by an individual, not through intermediaries or trusts.
Indirect holdings: Shares owned through another entity, such as a trust or family member, rather than held personally.
Derivative transaction: A trade involving financial contracts whose value is based on an underlying asset, such as stock options.
Weighted average purchase price: The average price paid per share, adjusted for the number of shares bought at each price.
Insider selling: When a company's executive, director, or major shareholder sells shares of their own company.
TTM: The 12-month period ending with the most recent quarterly report.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in DeFi Technologies to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in DeFi Technologies between May 12, 2025 and November 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DeFi Technologies Inc. ("DeFi Technologies" or the "Company") (NASDAQ: DEFT) and reminds investors of the January 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) DeFi Technologies was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for the Company; (ii) DeFi Technologies had understated the extent of competition it faced from other DAT companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly, Defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies' business and financial results; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On November 6, 2025, DeFi Technologies issued a press release purporting to report an arbitrage trade by DeFi Alpha. The press release disclosed, inter alia, that "[DAT]s have absorbed or delayed a significant share of arbitrage opportunities over the past year."

On this news, DeFi Technologies' stock price fell $0.13 per share, or 7.43%, to close at $1.62 per share on November 6, 2025.

Then, on November 14, 2025, DeFi Technologies issued a press release reporting its financial results for the third quarter of 2025. Among other items, DeFi Technologies reported a revenue decline of nearly 20%, falling well short of market expectations. The Company also significantly lowered its 2025 revenue forecast, from $218.6 million to approximately $116.6 million, and attributed this reduction to "a delay in executing DeFi Alpha arbitrage opportunities previously forecasted due to the proliferation of [DAT] companies and the consolidation in digital asset price movement in the latter half of 2025."

Concurrently, DeFi Technologies announced that Defendant Newton would leave his role as CEO and transition to an advisory position.

Following these disclosures, DeFi Technologies' stock price fell $0.40 per share, or 27.59%, over the following two trading sessions, to close at $1.05 per share on November 17, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding DeFi Technologies' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the DeFi Technologies class action, go to www.faruqilaw.com/DEFT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279952

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Intel unveiled new chip manufacturing milestones this week, but former Intel CEO Pat Gelsinger said the United States still has a long way to go to reclaim chip production from Asia.

"The metric [is] though, how many wafers are being built in America," Gelsinger said Friday on "The Claman Countdown."

"That is the only thing that matters," he added.

Gelsinger’s warning comes as the Trump administration has moved to strengthen U.S. chip manufacturing, taking a stake in Intel and pushing to bring advanced semiconductor production back on U.S. soil.

AMD CEO SAYS AI DEMAND IS 'GOING THROUGH THE ROOF' AS COSTS CLIMB

Patrick Gelsinger, former chief executive officer of Intel Corp., appears at the 2024 CES event in Las Vegas, Nevada, on Jan. 9, 2024. (David Paul Morris/Bloomberg via Getty Images / Getty Images)

Much of the world’s advanced chip manufacturing remains concentrated in Asia, particularly Taiwan. U.S. officials have said the imbalance poses economic and national security concerns.

Gelsinger said it is critical that manufacturing return to the United States, while cautioning that progress will take time.

"It’s hard to win that manufacturing back. You know it took decades for it to sediment into Asia. It doesn't come back quickly," he said.

NVIDIA LEADS AMERICA’S AI 'INDUSTRIAL REVOLUTION' WITH MAJOR MANUFACTURING MOVE

President Donald Trump met with Intel CEO Lip-Bu Tan at the White House this week, later praising the company on social media and calling the meeting "great."

Lip-Bu Tan, chief executive officer of Intel Corp., departs after a meeting at the White House in Washington, D.C., on Aug. 11, 2025. (Alex Wroblewski/Bloomberg via Getty Images / Getty Images)

The president also said the U.S. government is "proud to be a shareholder of Intel." In August, the U.S. government took a nearly 10% stake in the chipmaker as part of a broader national security push. Advanced computer chips are vital to the military, everyday electronics and other sectors to stay competitive in the AI race.

On Thursday, Tan responded to Trump’s praise, writing on X, "Honored and delighted to have the full support and encouragement of @POTUS @realDonaldTrump and @CommerceGov Secretary @howardlutnick as we bring leading edge chip manufacturing back to America!"

AI BREAKTHROUGHS AND FUTURISTIC GADGETS WOW CROWDS AT CES 2026 EXTRAVAGANZA

Gelsinger said major chip designers such as Nvidia and AMD still need to commit to manufacturing chips on American soil, calling those commitments part of Intel’s long-term strategy.

GET FOX BUSINESS ON THE GO

"All of those need to come back into the foundry of the U.S. and the foundry of Intel," Gelsinger added.

"I'm certainly encouraged to see these milestones, but we have a lot more to do."

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in F5 to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in F5 between October 28, 2024 and October 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - January 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against F5, Inc. ("F5" or the "Company") (NASDAQ: FFIV) and reminds investors of the February 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of F5's security capabilities; notably, that it was not truly equipped to safely secure data for its clients as F5 itself was, for all relevant times, experiencing a significant security breach (the "Security Breach") of some of its key offerings and, further, that the revelation of this breach would significantly impact F5's potential to capitalize on the security market.

On October 27, 2025, F5 announced their fourth quarter fiscal year 2025 results after the market closed, providing significantly below-market growth expectations for fiscal 2026 due in significant part to the Security Breach as the Company announced expected reductions to sales and renewals, elongated sales cycles, terminated projections, and increased expenses attributed to ongoing remediation efforts. Pertinently, defendants also disclosed that BIG-IP, the product that was the subject of the Security Breach, is the company's highest revenue product, elevating the scope of the impact from the original disclosure as F5 does not otherwise provide revenue contributions by product line.

Following this news, the price of F5's common stock declined dramatically. From a closing market price of $290.41 per share on October 27, 2025, F5's stock price fell to $258.76 per share on October 29, 2025, a decline of an additional 10.9% in the span of two days.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding F5's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the F5 class action, go to www.faruqilaw.com/FFIV or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279954

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

The seizures of sanctioned vessels have created a new flashpoint between the U.S. and Russia at sea.

, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025.

Preliminary, Unaudited Select Fourth Quarter 2025 Financial Results

Revenue of approximately $166.0 million for the three months ended December 31, 2025, representing 11% growth sequentially and 1% growth compared to the corresponding prior year period. Instruments revenue of approximately $15.5 million, representing 29% growth sequentially and a 36% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately $6.1 million of Single Cell instruments revenue, representing 24% growth sequentially and a 44% decrease year-over-year, and $9.4 million of Spatial instruments revenue, representing 32% growth sequentially and a 30% decrease year-over-year. Consumables revenue of approximately $141.7 million, representing 11% growth sequentially and a 6% increase as compared to the corresponding prior year period. Consumables revenue consists of approximately $100.8 million of Single Cell consumables revenue, representing 9% growth sequentially and 3% growth year-over-year, and $41.0 million of Spatial consumables revenue, representing 16% growth sequentially and 14% growth year-over-year. Services and License and Royalty revenue of approximately $8.8 million, representing a 3% decrease sequentially and 23% growth year-over-year. Preliminary, Unaudited Select Full Year 2025 Financial Results

Revenue of approximately $642.8 million for the year ended December 31, 2025. Excluding $44.1 million related to patent litigation settlements in the first and second quarters, full year 2025 revenue was approximately $598.7 million, representing a 2% decrease from the prior year. Instruments revenue of approximately $56.8 million, representing a 39% decrease from the prior year. Instruments revenue consists of approximately $22.7 million of Single Cell instruments revenue, representing a 36% decrease year-over-year and $34.1 million of Spatial instruments revenue, representing a 41% decrease year-over-year. Consumables revenue of approximately $507.2 million, representing 3% growth over the prior year. Consumables revenue consists of approximately $363.2 million of Single Cell consumables revenue, representing a 2% decrease year-over-year and $144.0 million of Spatial consumables revenue, representing 19% growth year-over-year. Services and License and Royalty revenue of approximately $34.8 million, excluding $44.1 million of upfront payments related to patent litigation settlements in the first and second quarters, representing 41% growth year-over-year. Increased cumulative Chromium instruments sold to more than 6,400 instruments and cumulative Spatial instruments sold to more than 1,500 as of the end of 2025. Single Cell consumables reactions sold increased by more than 20% compared to the prior year period. Cash, cash equivalents and marketable securities of approximately $520 million as of December 31, 2025. "I am incredibly proud of the tenacity and ingenuity our team displayed throughout 2025," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "While the macro environment was challenging, the team forged even stronger partnerships with customers, made important progress across our product roadmap and maintained tight operational discipline, leading to a significant strengthening of our balance sheet. I am confident that our greatest impact lies ahead and 10x is well positioned for the future."

J.P. Morgan Healthcare Conference
10x Genomics, Inc. is providing these updates in advance of its participation in the 44th Annual J.P. Morgan Healthcare Conference, which begins tomorrow. A live webcast of the company's presentation and question and answer session, which begins at 8:15 a.m. Pacific Time on Monday, January 12, 2026, will be available on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.

Preliminary Select Results Subject to Adjustment
10x Genomics, Inc. has not completed preparation of its consolidated financial statements for the fourth quarter or fiscal year of 2025. The select results presented in this news release for the fourth quarter and year ended December 31, 2025 are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete preparation of our consolidated financial statements for the year ended December 31, 2025. 10x Genomics, Inc. is in the process of completing its customary year-end close and review procedures as of and for the fourth quarter and year ended December 31, 2025, and there can be no assurance that final results for these periods will not differ from these estimates. During the course of the preparation of 10x Genomics, Inc.'s consolidated financial statements and related notes as of and for the year ended December 31, 2025, we or our independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary unaudited financial estimates presented herein.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s expected financial results for the fourth quarter and year ended December 31, 2025 and our future opportunities and performance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information available to management as of the date hereof. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results reflected in the forward-looking statements will be achieved or will occur. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K, 10-Q and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. 10x Genomics' products are for research use only (RUO) and are not for use in diagnostic procedures. "10x Genomics", "Chromium" and "Xenium" are trademarks of 10x. 10x trademarks are the sole property of 10x, and are subject to legal protection in the United States and/or certain other countries.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts
Investors: [email protected]
Media: [email protected]

SOURCE 10x Genomics, Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including an overview of key corporate objectives for 2026.

NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Fermi Inc. (NASDAQ: FRMI) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Fermi securities: (1) pursuant to the registration statement and prospectus issued in connection with the Company's October 2025 initial public offering ("IPO"); or (ii) between October 1, 2025, and December 11, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/FRMI.

Fermi Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:

the Company overstated its tenant demand for its Project Matador campus; the extent to which Project Matador would rely on a single tenant’s funding commitment to finance the construction of Project Matador; there was a significant risk that that tenant would terminate its funding commitment; and as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. What's Next for Fermi Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/FRMI. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Fermi you have until March 6, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Fermi Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Fermi Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.